Levi & Korsinsky notifies investors that it has commenced an investigation into Prelude Therapeutics Incorporated (NASDAQ: PRLD) concerning potential violations of the federal securities laws.
Prelude issued a press release on November 4, 2025, announcing its decision to pause the clinical development of its SMARCA2 degrader program. Prelude said that "[t]he decision to pause was based on a comprehensive review of clinical data generated to date and the Company's assessment of the capital and resource allocation required to advance the SMARCA2 program, versus the JAK2 and KAT6A programs, to key points of value inflection." Following this news, Prelude's stock price fell over 55% on November 4, 2025.
If you suffered a loss on your Prelude Therapeutics Incorporated securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





